Brief: Eton Pharmaceuticals Announces FDA Acceptance Of NDA Response For Dehydrated Alcohol Injection
11/01/2023 12:49
Jan 11 (Reuters) - Eton Pharmaceuticals Inc ETON.O :
* ETON PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA
RESPONSE
FOR DEHYDRATED ALCOHOL INJECTION
* ETON PHARMACEUTICALS INC - APPLICATION ASSIGNED A PDUFA
DATE OF
JUNE 27, 2023
* ETON PHARMACEUTICALS INC - PRODUCT PREVIOUSLY GRANTED
ORPHAN
DRUG DESIGNATION FOR METHANOL POISONING
Source text for Eikon: ID:nGNX3C9VTy
Further company coverage: ETON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer